<DOC>
	<DOCNO>NCT01140425</DOCNO>
	<brief_summary>The purpose study assess affect PF-00232798 QT interval . A prolonged QT interval risk factor arrhythmia .</brief_summary>
	<brief_title>Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and/or female subject nonchildbearing potential age 21 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . 12lead ECG demonstrate QTc &gt; 450 msec screening . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . History orthostatic symptom orthostatic hypotension screen . Pregnant nursing female ; female childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>PF-00232798</keyword>
	<keyword>CCR5</keyword>
	<keyword>QT</keyword>
	<keyword>QTc</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>